Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the dose ranges of peginesatide administered
intravenously or subcutaneously that maintained hemoglobin in participants on dialysis whose
hemoglobin values were stable on epoetin (alfa or beta).